-
Views
-
Cite
Cite
Endocrinology & Metabolism News, February 2007, The Journal of Clinical Endocrinology & Metabolism, Volume 92, Issue 2, 1 February 2007, Page 17a, https://doi.org/10.1210/jcem.92.2.9998
Close - Share Icon Share
Extract
Endocrine Discovery
Multibotanical therapy for vasomotor menopausal symptoms with either black cohosh or dietary soy, or black cohosh alone, was no more effective than placebo over 12 months in a randomized double-blind placebo controlled trial. (Ann Intern Med (Dec. 19, 2006) 145(12):869)
Among 3209 participants followed for first major cardiovascular events or death over a median 7 years, 10 biomarkers (including C-reactive protein, B-type natriuretic peptide, N-terminal pro-atrial natriuretic peptide, aldosterone, renin, fibrinogen, D-dimer, plasminogen-activator inhibitor type 1, homocysteine, and the urinary albumin-to-creatinine ratio) minimally improved risk classification beyond that predicted by conventional risk factors(N Engl J Med (Dec. 21, 2006) 355(25):2631)
Among 1099 postmenopausal women randomized after five years of alendronate therapy to either continued alendronate or switched to placebo for another five years, those who discontinued alendronate had greater risk of clinical vertebral fractures, but not non-vertebral fractures. Placebo-treated women had minor, but significant, decrements in bone density, although their levels remained greater than before treatment levels 10 years earlier. (JAMA (Dec. 27, 2006) 296(24):2927)
